瑞舒伐他汀钙治疗高胆固醇血症的有效性与安全性研究

目的探讨瑞舒伐他汀钙治疗高胆固醇血症的有效性和安全性，为临床安全用药提供参考。方法选择海南医学院附属医院2011年12月至2012年12月高胆同醇血症患者，经4周筛选出符合入选条件的患者129例，按随机数字表法分为3组。A组43例患者给予瑞舒伐他汀钙5mg治疗，B组43例患者给予10mg瑞舒伐他汀钙治疗，对照组43例患者给予10mg阿托伐他汀钙治疗，12周后对3组患者血脂指标进行观察，同时记录3组患者的不良反应。结果A组、B组、对照组治疗12周后LDL—C分别较治疗前降低2．2、2．3、1．8mmol／L；TC分别较治疗前降低2．2、2．3、1．8mmol／L；A组与B组下降幅度均大于对照组，组问比较差异有统计学意义（P〈0．05）。3组HDL—C较治疗前有明显升高，TG较治疗前明显降低，但组间比较差异无统计学意义（P〉0．05）。A组与B组无明显不良反应，对照组出现不良反应2例，其中1例为AST、ALT水平升高，不良反应发生率为4．6％。组间比较差异有统计学意义（P〈0．05）。结论瑞舒伐他汀钙能有效降低高胆固醇血症患者LDL—C、TC，具有显著的疗效与较高的安全性。

The research of efficacy and safety of rosuvastatin calcium for the treatment of hypercholesterolemia

Objective To research the efficacy and safety of rosuvastatin calcium for the treatment of hypercholesterolemia which can provide reference to drug safety. Methods Totally 129 patients who met the inclusion criteria from December 2011 to December 2012 were enrolled and divided into three groups. 43 patients of group A were treated with small doses of rosuvastatin calcium for 5 mg. 43 patients of group B were given 10mg rosuvastatin calcium. 43 cases of the control group were treated with atorvastatin calcium for 10 mg. After 12 weeks, the adverse reactions of the three groups were observed. Results After 12 weeks, the LDL-C of group A,group B and group C were lower 2.16 mmol/L,2.26 mmol/L and 1.8 mmol/L. TC were 2.21 mmol/L, 2. 28 mmol/L, 1.79 mmol/L, lower than before treatment （P 〈 0.05）. The HDL-C of three groups was significantly higher than that before treatment. TG was significantly lower than before treatment （P 〉 0.05）. Group A and group B had no significant adverse reactions. But the control group had one case of aspartate aminotransferase. The adverse reaction rate was 4.65%. The difference was significant （P 〉 0.05）. Conclusion Rosuvastatin calcium can effectively reduce the LDL-C and TC of hypercholesterolemia.